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Alcohol consumption has been inconsistently associated with breast cancer risk. Recent studies suggest that genetic polymorphisms
of glutathione S-transferases (GSTs) may modify this relation. To determine if breast cancer risk is associated with GSTM1 and
GSTT1 genetic polymorphisms, and to evaluate the effect modification between GST genotypes and alcohol consumption in the risk
of breast cancer, we conducted a case–control study in the state of Connecticut in the period 1998 and 2001. Cases were
histologically confirmed, incident breast cancer patients in New Haven County, CT. Controls were randomly selected from women
histologically confirmed to be without breast cancer. The study results show that, while GSTM1 genotypes were not associated with
breast cancer risk, GSTT1-null genotype was associated with a significant 90% increased risk for postmenopausal women (OR¼1.9,
95% CI 1.2–3.0). Analysis by GST genotypes and alcohol consumption shows that GSTM1A ever-drinking women had a 2.5-fold
(OR¼2.5, 95% CI 1.1–5.5) increased risk of breast cancer compared to the GSTM1A never-drinkers, and the risk increases with
duration and daily amount of alcohol consumption. Postmenopausal women with GSTT1-null genotype, who consumed a lifetime of
4250kg of spirit-equivalents, had an almost seven-fold increased risk (OR¼6.8, 95% CI 1.4–33.9), and drinking commencing at
younger ages appears to carry a higher risk. An OR of 8.2 (95% CI 1.2–57.4) was observed for those with GSTM1A, and GSTT1-null
genotypes who had consumed a lifetime of 4250kg of spirit-equivalents. In conclusion, alcohol consumption may increase breast
cancer risk among those who carry susceptible GST genotypes.
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Human glutathione S-transferases (GSTs) are considered to be
particularly important for detoxifying many carcinogenic com-
pounds and reactive intermediates that may be breast carcinogens
(Ketterer, 1988; Hayes and Pulford, 1995; Smith et al, 1995;
Rebbeck, 1997). Subjects with different GST genotypes may
therefore have different susceptibilities to environmental expo-
sures.
About 50% of the Caucasian population carries a homozygous
deletion of the GSTM1 locus, resulting in an inactive gene product
(null genotype), and the lack of functional GSTM1 enzyme activity.
Studies have shown that individuals who inherit the GSTM1 null
genotype are not capable of conjugating and detoxifying specific
substrate epoxide intermediates (Wiencke et al, 1990). Thus, the
absence of the GSTM1 gene should increase cancer risk from
environmental exposure while the presence of the intact GSTM1
gene would be protective for cytogenetic damage and carcinogen-
derived DNA adduct formation. The GSTT1 gene, located on
chromosome 6, is absent from about 40% of the population
(Pemble et al, 1994). GSTT1 has also been involved in the
glutathione-dependent detoxification. Similar to GSTM1, GSTT1
has significant activity towards epoxides, suggesting that indivi-
duals without both GSTM1 and GSTT1 may be at a particularly
high risk of cancer (Wiencke et al, 1995). Moreover, the results of
recent studies suggest that for alcohol drinkers interactions with
GSTM1 and GSTT1 deletion polymorphisms may play an
important role in individual susceptibility to breast cancer
(Helzlsouser et al, 1998; Park et al, 2000).
In this case–control study, we sought to determine if the
polymorphisms of GSTM1 and GSTT1 modify the relationship
between alcohol drinking and breast cancer risk based on detailed
information on lifetime alcohol consumption.
MATERIALS AND METHODS
Study subjects
This study used blood samples and data collected from a recently
completed case–control study of female breast cancer in
Connecticut. The detailed description of the study population
and the methods have been described elsewhere (Zheng et al,
2000, 2002). Briefly, cases were histologically confirmed, incident
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New Haven Hospital (YNHH), in New Haven County, Connecticut
in 1994–1997. Patients were 30–80 years old. Potentially eligible
cases were identified using computerised patient information from
YNHH, where records of all newly completed breast-related
surgeries are kept. We consecutively selected all breast cancer
patients who met the study eligibility requirements as described
above. A total of 326 incident breast cancer patients were recruited.
The participation rate was 77% for patients.
In order to avoid selection of controls with nondiagnosed
early-stage breast cancer or precancerous conditions, we randomly
selected controls from the same computerised files from
those who had had breast-related surgery but were histologically
confirmed to be without breast cancer. A total of 347 controls
were selected and frequency matched to the cases by age, within
5-year intervals (30–34,y). The participation rate was 71%
for controls.
Interviews
After approval by each subject’s hospital and physician, potential
participants were approached by letter and then by phone. Those
who consented were interviewed by a trained interviewer, either at
home or at a location convenient for the patient. A standardised,
structured questionnaire was used to obtain information on
alcohol drinking, tobacco smoking, menstrual and reproductive
history, lactation history, past medical history, family cancer
history, occupation, diet and demographic factors. Information on
lifetime alcohol consumption included the type of alcoholic
beverage used, age at which drinking commenced, amount of
alcohol consumed per day, the frequency with which the subject
consumed each type of alcoholic beverage, the duration during
which each type of alcoholic beverage was consumed and total
duration of drinking.
Blood collection and laboratory analysis of GST genotypes
As recently reported elsewhere (Zheng et al, 2002), blood clot
samples were sent in batches to the study laboratory at the
University of Texas at MD Anderson Cancer Center to isolate high
molecular weight genomic DNA for GST genotyping. DNA purity
and yield were assessed by determining the optical densities at 260
and 280nm. Genotyping of GSTM1 and GSTT1 was performed
using a combination of PCR and RFLP analysis, using a
modification of a previously described method (Fryer et al,
1993a,b). Amplification was performed with the GSTM1- and
GSTT1-specific primers. The PCR product was electrophoresed in
2% agarose, stained in 0.5% ethidium bromide and photographed
under UV illumination. Cell lines (human malignant gliomas and
breast carcinoma) available in our study laboratory and represent-
ing GSTT1-positive, GSTT1-null, GSTM1A, GSTM1B and GSTM1-
null polymorphisms were used as positive controls. Quality control
procedures implemented for the GST genotype analyses included
the running of controls of stable human cancer cell lines with a
known polymorphic GST gene and reanalysing samples that
yielded ambiguous results. Samples were coded and batched at
Yale, and the laboratory personnel at the MD Anderson Cancer
Center were blinded to their identity.
Data analysis
Unconditional logistic regression was used to estimate the
association between GSTM1 and GSTT1 genetic polymorphisms
and breast cancer risk, to evaluate the putative modification by
Table 1 GSTM1 genotypes, alcohol consumption and breast cancer risk
GSTM1-A GSTM1-B GSTM1-null
Alcohol drinking Ca/Co
a OR
b (95% CI) Ca/Co
a OR
b (95% CI) Ca/Co
a OR
b (95% CI)
Never 13/23 1.0 5/4 1.0 20/23 1.0
Ever 93/79 2.5 (1.1/5.5)
c 36/40 0.8 (0.2/3.3) 145/150 1.1 (0.6/2.3)
Age when started drinking (y)
o18 18/19 2.1 (0.8/5.6) 5/11 0.4 (0.1/2.2) 26/28 1.4 (0.6/3.3)
18–24 56/47 2.4 (1.0/5.6) 25/24 0.9 (0.2/3.9) 97/96 1.2 (0.6/2.4)
>24 19/13 3.2 (1.1/9.1) 6/5 0.9 (0.1/6.1) 22/26 0.9 (0.4/2.1)
P for trend 0.14 0.86 0.99
Spirit-equivalent drinking per day (g)
o80 16/19 2.1 (0.8/6.0) 9/11 0.6 (0.1/3.1) 35/31 1.2 (0.5/2.7)
80–150 32/29 2.0 (0.8/5.1) 11/16 0.6 (0.1/3.0) 54/67 1.0 (0.5/2.0)
>150 45/31 3.1 (1.3/7.6) 16/13 1.1 (0.2/5.3) 56/52 1.3 (0.6/2.8)
P for trend 0.07 0.15 0.87
Years of drinking
o15 13/19 1.7 (0.6/4.7) 9/5 1.9 (0.3/13.3) 23/23 1.3 (0.5/3.1)
15–30 38/41 1.9 (0.8/4.5) 14/22 0.6 (0.1/3.0) 62/74 1.2 (0.6/2.6)
>30 42/19 4.2 (1.6/10.9) 13/13 0.8 (0.2/3.8) 60/53 1.0 (0.5/2.2)
P for trend 0.01 0.31 0.93
Lifetime kilograms of spirit-equivalent drinking
o70 20/24 1.9 (0.7/5.0) 10/14 0.5 (0.1/2.8) 37/44 1.0 (0.4/2.1)
70–250 23/28 1.7 (0.6/4.4) 10/11 0.9 (0.2/4.8) 44/34 1.6 (0.7/3.6)
>250 50/27 3.4 (1.4/8.2) 16/15 0.9 (0.2/4.1) 64/72 1.0 (0.5/2.1)
P for trend 0.03 0.19 0.87
aCases/controls.
bAdjusted for age, BMI (o21, 21–24, >24), age at first full-term pregnancy nulliparous (o20, 20–25, >25 y), lifetime duration of lactation (never, 1–5, 6–11, >11 months),
family breast cancer history and menopausal status.
cBold entries for statistical significance.
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breast cancer, and to control for potential confounders. The
average adult lifetime daily consumption of alcohol in grams and
the total lifetime consumption in kilograms of spirit- equivalents
were calculated by taking into account the frequency, the amount
and the duration of consumption of each type of alcoholic
beverage. For these analyses, grams of beer and fruit wine were
converted into grams of spirit-equivalents as follows: grams of beer
were divided by 8, grams of wine by 2, according to the
approximate ratio of alcohol contents in beverages. Each amount
was then multiplied by the weekly reported frequency of
consumption of each type of alcoholic beverage and further
divided by 7 to estimate average daily consumption. Finally, the
total lifetime kilograms of spirit-equivalent consumption was
estimated.
Variables included in the final model were age (as a continuous
variable), body mass index (o21, 21–24, X25 weight in
kilograms/square of height in meters), lifetime months of lactation
(0, 1–5, 6–11, 411 months), age at first full-term pregnancy
(nulliparous, o20, 20–25, 425 years), family breast cancer
history and menopausal status. Additional adjustment for other
variables such as age at menarche, age at menopause, number of
live births and use of exogenous hormones did not result in
material change for the observed association; therefore, these
variables were not included in the final model. Maximum
likelihood estimates of the parameters were obtained using SAS
(SAS Institute, 1990).
RESULTS
Neither of the GSTM1 allelotypes were significantly associated with
breast cancer risk for all women combined or among pre- or
postmenopausal women (data not shown). Among women with
GSTT1-null genotype, however, there was a significant, 50%,
increase in breast cancer risk for all women combined (OR¼1.5,
95% CI 1.0–2.2). Further analysis by menopausal status indicates
that this risk was limited to postmenopausal women (OR¼1.9,
95% CI 1.2–3.0).
Table 1 presents the association between alcohol consumption
and breast cancer risk by GSTM1 genotype. There was no
increased risk associated with alcohol consumption for women
with GSTM1B and GSTM1-null genotypes. There was, however, a
significantly increased risk for women with GSTM1A genotypes.
As shown in Table 1, GSTM1A ever-drinking women had a 2.5-fold
(OR¼2.5, 95% CI 1.1–5.5) increased risk of breast cancer
compared to the GSTM1A never-drinkers. Furthermore, the risk
seems to increase with duration and daily amount of alcohol
consumption. For those who drank more than 150g of spirit-
equivalents daily, the OR was 3.1 (95% CI 1.3–7.6). For those who
had more than 30 years of alcohol consumption, the OR was 4.2
(95% CI 1.6–10.9). For those with a lifetime of more than 250kg of
spirit-equivalent consumption, the OR was 3.4 (95% CI 1.4–8.2).
Further stratification by menopausal status indicates that the
observed significant association is limited to postmenopausal
women (data not shown). For example, ever-drinking postmeno-
pausal women, who had a GSTM1A genotype, had a three-fold
(OR¼3.1, 95% CI 1.1–8.4) significantly increased risk of breast
cancer, while ever-drinking premenopausal women did not
(OR¼1.4, 95% CI 0.3–6.1).
The relation between alcohol consumption and breast cancer
risk by GSTT1 genotype is presented in Table 2. There was no
increased risk associated with alcohol consumption for women
with GSTT1-positive genotype; however, there was a trend of an
effect for women with GSTT1-null genotype, as evidenced (Table 2)
by a 60%, albeit statistically insignificant, increase in breast cancer
Table 2 GSTT1 genotypes, alcohol consumption and breast cancer risk
GSTT1-positive GSTT1-null
Alcohol drinking Ca/Co
a OR
b (95% CI) Ca/Co
a OR
b (95% CI)
Never 30/41 1.0 10/11 1.0
Ever 192/219 1.2 (0.7/2.0) 85/63 1.6 (0.6/4.4)
Age when started drinking (y)
o18 37/50 1.2 (0.6/2.2) 14/9 2.1 (0.5/8.2)
18 24 126/132 1.3 (0.7/2.3) 52/41 1.5 (0.5/4.5)
>24 29/37 1.0 (0.5/2.0) 19/13 1.5 (0.5/5.1)
P for trend 0.92 0.91
Spirit-equivalent drinking per day (g)
o80 41/51 1.0 (0.5/1.9) 19/13 1.8 (0.5/6.1)
80–150 62/92 0.9 (0.5/1.7) 36/26 1.5 (0.5/4.4)
>150 89/76 1.6 (0.9/2.9) 30/24 1.6 (0.5/5.1)
P for trend 0.20 0.46
Years of drinking
o15 32/32 1.4 (0.7/2.9) 13/17 1.1 (0.3/3.7)
15–30 74/114 0.9 (0.5/1.7) 42/29 2.1 (0.7/6.6)
>30 86/73 1.4 (0.8/2.6) 30/17 1.5 (0.5/4.8)
P for trend 0.49 0.38
Lifetime kilograms of spirit-equivalent drinking
o70 45/62 1.0 (0.5/1.9) 22/24 1.1 (0.3/3.4)
70–250 51/54 1.4 (0.7/2.6) 27/20 1.4 (0.4/4.5)
>250 96/103 1.2 (0.7/2.2) 36/19 2.4 (0.8/7.6)
P for trend 0.20 0.04
See Table 1.
Table 3 Alcohol drinking and breast cancer risk for subjects with
GSTT1-null genotype
Premenopausal Postmenopausal
Alcohol drinking Ca/Co
a OR
b (95% CI) Ca/Co
a OR
b (95% CI)
Never 3/4 1.0 7/7 1.0
Ever 21/30 0.8 (0.1/4.9) 64/33 2.3 (0.6/8.3)
Age when started drinking (y)
o18 5/6 1.0 (0.1/9.9) 9/3 3.2 (0.5/21.9)
18–24 12/19 0.8 (0.1/5.0) 40/22 2.4 (0.6/9.6)
>24 4/5 0.9 (0.1/8.0) 15/8 1.8 (0.4/8.3)
P for trend 0.82 0.99
Spirit-equivalent drinking per day (g)
o80 7/6 1.4 (0.2/11.7) 12/7 1.9 (0.4/9.4)
80–150 6/10 0.8 (0.1/6.1) 30/16 2.2 (0.6/8.6)
>150 8/14 0.6 (0.1/4.1) 22/10 3.1 (0.6/15.1)
P for trend 0.64 0.18
Years of drinking
o15 6/8 1.2 (0.1/9.0) 7/9 0.9 (0.2/5.0)
15–30 15/18 1.2 (0.2/7.8) 27/11 2.9 (0.6/13.1)
>30 0/4 30/13 2.6 (0.6/10.8)
P for trend 0.25 0.11
Lifetime kilograms of spirit-equivalent drinking
o70 8/11 0.9 (0.1/5.7) 14/13 1.0 (0.2/4.7)
70–250 8/8 1.1 (0.1/8.3) 19/12 1.5 (0.3/7.3)
>250 5/11 0.6 (0.1/4.6) 31/8 6.8 (1.4/33.9)
P for trend 0.64 0.03
aCases/controls.
bAdjusted for age, BMI (o21, 21–24, >24), age at first full-term pregnancy
nulliparous (o20, 20–25, >25 y), lifetime duration of lactation (never, 1–5,
6–11, >11 months), family breast cancer history.
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(‘ever-drinkers’). Stratifying women by menopausal status and
alcohol consumption revealed that this apparent effect was
significant for postmenopausal women.
The data suggest that the more alcohol that postmenopausal
women with GSTT1-null genotype consume, the greater their risk
of breast cancer (Table 3). Specifically, Table 3 shows that women
who consumed a lifetime of more than 250kg of spirit-equivalents
had an almost seven-fold increased risk of breast cancer (OR¼6.8,
95% CI 1.4–33.9). This was supported by observations that the
risk increases with increasing duration and daily amount of
alcohol consumption, with drinking commencing at younger ages
appearing to carry a higher risk, although these results were not
statistically significant.
Table 4 presents the joint effects of GSTM1, GSTT1 genotypes
and alcohol consumption (lifetime kilograms of spirit-equivalent
consumption) in the development of breast cancer. A statistically
significant eight-fold (OR¼8.2, 95% CI 1.2–57.4) increased risk of
breast cancer was observed for those with GSTM1A, and GSTT1-
null genotypes who had consumed a lifetime total of more than
250kg of spirit-equivalents. Subjects with GSTT1-positive and
GSTM1A genotypes who consumed a lifetime total of more than
250kg of spirit-equivalents also showed a significantly increased
risk of breast cancer (OR¼2.3, 95% CI 1.1–4.7). No significantly
increased risk was observed for other GSTM1 and T1 genotype
combinations.
DISCUSSION
The results of this study suggest that there is an increased risk of
breast cancer associated with alcohol consumption among those
carrying certain genotypes. We found that postmenopausal women
with a GSTM1A genotype have an increased risk of breast cancer
when they drink, and the risk increases with increasing amount
and duration of alcohol consumption. We also found that breast
cancer risk is increased for postmenopausal women with the
GSTT1-null genotype who consume more than 250kg of spirit-
equivalents. An eight-fold significantly increased risk was observed
among heavier drinkers who had GSTM1A and GSTT1-null
genotypes.
Alcohol consumption has previously been associated with breast
cancer risk, but the results have been inconsistent (Rosenberg et al,
1993). It has been postulated that alcohol may influence the risk of
breast cancer through effects on pituitary-prolactin secretion,
metabolism and clearance of Oestrogen by the liver, or pineal-
melatonin production (Willett et al, 1989; Hiatt, 1990). Other
potential mechanisms may include alcohol-facilitated transport of
carcinogens to breast tissue, alcohol disruption of membrane
function, or immunoincompetence through the promotion of
nutritional deficiencies or liver disease (Rosenberg et al, 1993).
Alcohol may also induce the formation of free radicals and a rise of
lipid peroxidation which can lead to DNA damage (Wright et al,
1999).
GSTs are involved in the metabolism of a wide variety of
potential carcinogenic compounds, including peroxides, organic
epoxides, aromatic amino/nitro compounds and steroids. GST
isozymes, such as GSTM1 and GSTT1, have distinct but over-
lapping substrate specificity as reviewed by Helzlsouser et al
(1998). Thus, GSTs could interact with alcohol or its contaminants
in the development of breast cancer. For example, lack of GST
genes could reduce the capacity to conjugate lipid peroxidation
products, cytotoxic compounds and free radicals generated during
alcohol metabolism (Park et al, 2000). Thus, the inconsistent
results relating alcohol consumption to breast cancer risk might be
explained by genetic differences in detoxification enzymes in the
study populations. An increased risk of breast cancer associated
with alcohol consumption may be apparent only among those
carrying putative high-risk genotypes.
The role of GSTT1 in the risk of breast cancer is supported
by earlier studies (Helzlsouser et al, 1998; Park et al, 2000).
Lack of GSTT1-mediated conjugation could result in an increase
in the risk for those with exposure to alcohol, its by-products
or its contaminants. The biological mechanisms underlying
our observations about GSTM1A are less clear. Although
previous studies observed a significant interaction between
GSTM1-null, GSTT1-null genotypes and alcohol consumption
in the risk for breast cancer among premenopausal women
(Park et al, 2000) and among both pre- and postmenopausal
women (Helzlsouser et al, 1998), the potential association
between individual GSTM1 alleles and breast cancer or their
interaction with alcohol consumption in modifying the risk of
breast cancer was not investigated. Our findings in this study are,
however, consistent with those in several reports indicating
potential differences in the effects of GSTM1A and GSTM1B in
breast and other cancers (Fryer et al, 1993a,b; Duncan et al, 1995;
Inskip et al, 1995; Charrier et al, 1999). There is also the possibility
that GSTM1 may be linked to another gene involved in the
metabolism of putative breast carcinogens. Indeed, there are
reports indicating that GSTM1 is linked to GSTM3 (Inskip et al,
1995) and GSTP1 (Maugard et al, 2001), and thus the effect of
GSTM1 on cancer susceptibility may be influenced by the
expression of GSTP1 and/or GSTM3, suggesting that interactions
between GST genes may be a significant factor in determining
cancer susceptibility.
A potential limitation of this study and other earlier studies
(Zhong et al, 1993; Ambrosone et al, 1995; Bailey et al, 1998;
Charrier et al, 1999; Garcia-Closas et al, 1999) that investigated
the association between GST genotypes alone or their interaction
with alcohol consumption in the risk of breast cancer is the
relatively small sample sizes. Therefore, chance may explain the
inconsistent results linking GST genotypes, alcohol drinking and
breast cancer. For example, the study by Helzlsouser et al (1998)
involved 110 cases and 113 controls, and the study by Park et al
(2000) involved 189 cases and an equal number of controls.
Although our study has a sample size of 326 cases and 347
controls, this is still relatively small, especially after stratification
by GST genotype and menopausal status. Studies with larger
sample size from different populations are clearly needed to
address the issue.
In conclusion, this is the first study using detailed information
on lifetime alcohol consumption to examine the effect of alcohol
consumption on the risk of breast cancer by GST genotypes. The
results of this study suggest that alcohol consumption may
increase breast cancer risk among those who carry susceptible
Table 4 GSTM1, GSTT1 genotypes, alcohol consumption and breast
cancer risk
Lifetime kilograms of spirit-equivalent drinking
p p250 >250
GST genotypes Ca/Co
a OR Ca/Co
a OR
b (95% CI)
GSTT1-Null
GSTM1-Null 27/26 1.0 19/14 1.3 (0.4/4.0)
GSTM1-A 23/20 1.0 11/2 8.2 (1.2/57.4)
GSTM1-B 7/7 1.0 6/2 8.9 (0.6/130.7)
GSTT1-Positive
GSTM1-Null 74/75 1.0 45/58 0.8 (0.5/1.3)
GSTM1-A 33/55 1.0 39/25 2.3 (1.1/4.7)
GSTM1-B 18/22 1.0 10/13 0.9 (0.3/2.7)
See Table 1.
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British Journal of Cancer (2003) 88(1), 58–62 & 2003 Cancer Research UKGST genotypes. A potential effect modification between GST
genotypes and alcohol consumption in the development of breast
cancer is biologically plausible. If this association is causal, the
high frequency of the at-risk GST genotypes in the population
means that avoidance of exposure among individuals with these
susceptibility genotypes should result in a substantial reduction of
breast cancer cases. If future studies demonstrate that alcohol
consumption is, indeed, a risk factor for breast cancer among
individuals with high-risk GST genotypes, alcohol consumption
would be one of the few modifiable risk factors for breast cancer
identified to date.
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